[https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/](https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/)
“MASH will be pharma’s hottest bidding war, with multiple $5 billion-plus deals and at least one blockbuster acquisition that scoops up an entire liver-disease platform. With a wave of late-stage clinical readouts approaching, large pharma players that still lack a meaningful position in MASH are likely to act aggressively if key datasets further derisk these assets. Companies with differentiated mechanisms and advanced clinical programs, including leaders like Madrigal Pharmaceuticals and **Altimmune**, could become attractive acquisition targets as MASH consolidates into a platform-level race.”
*Jessica Owens, co-founder, Initiate Ventures*